Explore Our Library of Biomanufacturing Resources & Technical Data

Application Notes

Cellastim S – Reconstitution Application Note

rHSA Reconstitution Video Protocol

A Binding Advantage: Optibumin 25 Demonstrates Enhanced Drug Binding and Consistency over Plasma Albumin

Enhanced Cryopreservation of T Cells Using Optibumin®, Recombinant Human Serum Albumin (rHSA)

Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note

High-Resolution Analytical Characterization of Optibumin®: Structural Homogeneity and Functional Consistency Compared to Plasma-Derived HSA

Improved iPSC Cryopreservation with Optibumin 25: Enhanced Viability, Expansion, and Pluripotency

Low-DMSO Cryopreservation of MSCs with Optibumin 25 Recombinant Albumin

Maintaining Viable Cell Count in Primary T Cells During Cell Washing Using Optibumin®

Recombinant Albumin as a Carrier Protein Improves Cytokine Recovery and Functional Stability at Dilute Concentrations

Retain and Protect Final Cell Product with Optibumin®, a Recombinant Human Serum Albumin (rHSA)

Superior Cryopreservation of T Cells in Low-DMSO, Animal-Origin-Free Formulation Using Optibumin 25 and PentaHibe Base

T Cell Cryopreservation Using Exbumin®, Recombinant Human Serum Albumin, and Reduced DMSO

Thiol by Combat: Enhanced Covalent Conjugation with Recombinant Albumin Compared to Human Plasma-Derived Albumin

Blog

Albumin in Drug Delivery: Cancer’s Unexpected Achilles’ Heel

Consistency Is the New Compliance

Cryopreservation Just Got Better with Optibumin® 25

Evolving Challenges in Closed-System Biomanufacturing

How Regulatory Bodies Are Driving the Shift to Animal-Origin-Free Solutions in Cell Therapy and Vaccine Development

Innovative Solutions in Closed-System Biomanufacturing: Exploring the Tools and Technologies Driving Sterility and Efficiency

Optibumin vs Traditional Albumin: Comparing Performance in Cell Wash Applications

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

Solving the Vaccine Supply Challenge

The “Cheap” Albumin Paradox: The Actuarial Cost of Serum Albumin in Biomanufacturing

Why Border Disruptions Threaten Blood-Derived Raw Materials—and What Biomanufacturers Can Do About It

Why Do Some Biologics Cross the Finish Line—While Others Crash and Burn?

Catalog

InVitria Product Catalog – 2025

Data Sheets

Cellastim S – Data Sheet

Exbumin – Data Sheet

Optibumin 20 – Data Sheet

Optibumin 25 – Data Sheet

Infographics

Optimizing CAR-T Manufacturing with Defined, AOF Components

Journal Articles (DOI Links)

Utilization of Recombinant Albumins in the Expansion of Human T Lymphocytes

Accurate nanoelectrode recording of human pluripotent cell-derived cardiomyocytes for assaying drugs and modeling disease

News

InVitria Launches Optibumin 25 rHSA

Posters

Addressing Vaccine Stability And Cold Chain Challenges With Recombinant Human Serum Albumin To Enable Global Administration

Advancing Vaccine Excellence

Better Cells, Better Outcomes: Improving CAR-T Manufacturing with Animal-Free Cryopreservation and Wash Solutions

Stronger Cells for Safer Therapies: Low-DMSO, Animal-Origin-Free T Cell Cryopreservation with Optibumin 25 and PentaHibe

Virus Yield Improvement for Downstream Processing: Exbumin®, Excipient Recombinant Albumin

SDS

Exbumin – Safety Data Sheet

Optibumin – Safety Data Sheet

Cellastim S – Safety Data Sheet

Use Guidelines

Cellastim S – Guidelines for Use

Exbumin – Guidelines for Use

Optibumin 20 – Guidelines for Use

Optibumin 25 – Guidelines for Use

Webinar

Accelerating Vaccine Development Through Use of Blood-Free Components

Why Cell Quality Erodes During Downstream Processing — and How to Prevent It | Webinar

White Papers

High-Quality Recombinant Human Serum Albumin (rHSA), Exbumin™, for Improved Cell Wash Buffer Preparation

Cellastim S – Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells

Emergence of Blood-Free Recombinant Human Albumin

Optimizing the Performance of LNP and Liposome Therapeutics with Blood-Free Recombinant Albumin